Short-term periodic consumption of multiprobiotic from childhood improves insulin sensitivity, prevents development of non-alcoholic fatty liver disease and adiposity in adult rats with glutamate-induced obesity

BMC Complementary and Alternative Medicine

Tetyana Beregova²  Tetyana Falalyeyeva²  Oleksandr Virchenko²  Maryana Kondro¹  Nazarii Kobyliak³  Oleksandr Savcheniuk² 

[1]Danylo Halytsky Lviv National Medical University, Pekarska Str., 69, Lviv 79010, Ukraine

[2]Taras Shevchenko National University of Kyiv, Volodymyrska Str., 64/13, Kyiv 01601, Ukraine

[3]Bogomolets National Medical University, T. Shevchenko boulevard, 13, Kyiv 01601, Ukraine

关键词: Non-alcoholic fatty liver disease;    Insulin;    Adiponectin;    Leptin;    Glutamate;    Obesity;    Probiotics;   

Others  :  1087323
DOI  :  10.1186/1472-6882-14-247

 received in 2014-04-11, accepted in 2014-07-11,  发布年份 2014

【 摘 要 】

Background

Today the impairment of metabolism and obesity are being extensively investigated due to the significant increase of the prevalence of these diseases. There is scientific evidence that probiotics are beneficial for human health. Thus, the aim of the study was to investigate the effect of multiprobiotic “Symbiter acidophilic concentrated” on obesity parameters in the rats under experimental obesity.

Methods

The study was carried out on 60 newborn Wistar rats, divided into 3 groups, 20 animals in each (females – n = 10, males – n = 10): intact rats, monosodium glutamate (MSG-) and MSG + probiotic group. Rats of intact group were administered with saline (8 μl/g, subcutaneously (s.c.)). Newborns rats of MSG-group and MSG + probiotic group were injected with a solution of MSG (4.0 mg/g) s.c. at 2^nd – 10^th postnatal days. The MSG + probiotic group was treated with 140 mg/kg (1.4 × 10¹⁰ CFU/kg) of multiprobiotic “Symbiter”. MSG-group was treated with 2.5 ml/kg of water (per os) respectively. Administration was started at the age of 4 weeks just after wean and continued for 3 month intermittently alternating two-week course of introduction with two-week course of break.

Results

Neonatal treatment with MSG caused a stunted growth in both MSG-groups, which manifested with significantly smaller naso-anal length compared to adult intact rats. There was no significant difference in weight between intact and MSG-groups on 120^th day. The adiponectin level in the serum of rats with MSG-induced obesity decreased by 2.43 times (p = 0.001) in males and 1.75 (p = 0.020) in females. Concentration of leptin in adipose tissue were significantly higher by 45.9% (p = 0.019) and 61.2% (p = 0.009) respectively in males and females compared to intact rats. Our study has indicated that daily oral administration of multiprobiotic to neonatal MSG-treated rats by 2-week courses led to significant reduce of total body and VAT weight with subsequent improvement in insulin sensitivity and prevention of non-alcoholic fatty liver (NAFLD) development.

Conclusions

These results have shown that periodic treatment with multiprobiotic prevents the MSG-induced obesity and NAFLD development.

【 授权许可】

   
2014 Savcheniuk et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 5.

Figure 1.

Figure 8.

Figure 9.

Figure 10.

【 参考文献 】

• [1]Visscher TL, Seidell JC: The public health impact of obesity. Annu Rev Public Health 2001, 22:355-375.
• [2]Flier JS: Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004, 116:337-350.
• [3]Jiang J, Ahn J, Huang WY, Hayes RB: Association of obesity with cardiovascular disease mortality in the PLCO trial. Prev Med 2013, 57:60-64.
• [4]Jung DH, Kim JY, Kim JK, Koh SB, Park JK, Ahn SV: Relative contribution of obesity and serum adiponectin to the development of hypertension. Diabetes Res Clin Pract 2014, 103(1):51-56.
• [5]Janghorbani M, Momeni F, Dehghani M: Hip circumference, height and risk of type 2 diabetes: systematic review and meta-analysis. Obes Rev 2012, 13:1172-1181.
• [6]Takahashi H, Hosono K, Endo H, Nakajima A: Colon epithelial proliferation and carcinogenesis in diet-induced obesity. J Gastroenterol Hepatol 2013, 28(Suppl 4):41-47.
• [7]Ntikoudi E, Kiagia M, Boura P, Syrigos KN: Hormones of adipose tissue and their biologic role in lung cancer. Cancer Treat Rev 2013, 40:22-30.
• [8]Eichholzer M, Huang DJ, Modlasiak A, Schmid SM, Schotzau A, Rohrmann S, Guth U: Impact of body mass index on prognostically relevant breast cancer tumor characteristics. Breast Care (Basel) 2013, 8:192-198.
• [9]Ward KK, Roncancio AM, Shah NR, Davis MA, Saenz CC, McHale MT, Plaxe SC: The risk of uterine malignancy is linearly associated with body mass index in a cohort of US women. Am J Obstet Gynecol 2013, 209:579. e571-575
• [10]van Dorp W, Blijdorp K, Laven JS, Pieters R, Visser JA, van der Lely AJ, Neggers SJ, van den Heuvel-Eibrink MM: Decreased ovarian function is associated with obesity in very long-term female survivors of childhood cancer. Eur J Endocrinol 2013, 168:905-912.
• [11]Obesity and overweight [http://www.who.int/mediacentre/factsheets/fs311/en/ webcite]
• [12]Kopelman PG, Caterson ID, Stock MJ, Dietz WH: Clinical obesity in adults and children: In Adults and Children. Oxford: Blackwell Publishing; 2005.
• [13]Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI: The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004, 101:15718-15723.
• [14]Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI: Host-bacterial mutualism in the human intestine. Science 2005, 307:1915-1920.
• [15]Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI: Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 2005, 102:11070-11075.
• [16]Turnbaugh PJ, Backhed F, Fulton L, Gordon JI: Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 2008, 3:213-223.
• [17]Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI: An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444:1027-1031.
• [18]Lee SJ, Bose S, Seo JG, Chung WS, Lim CY, Kim H: The effects of co-administration of probiotics with herbal medicine on obesity, metabolic endotoxemia and dysbiosis: A randomized double-blind controlled clinical trial. Clin Nutr 2014. in press
• [19]Luoto R, Collado MC, Salminen S, Isolauri E: Reshaping the gut microbiota at an early age: functional impact on obesity risk? Ann Nutr Metab 2013, 63(Suppl 2):17-26.
• [20]Savcheniuk OA, Virchenko OV, Falalyeyeva TM, Beregova TV, Babenko LP, Lazarenko LM, Demchenko OM, Bubnov RV, Spivak MY: The efficacy of probiotics for monosodium glutamate-induced obesity: dietology concerns and opportunities for prevention. EPMA J 2014, 5:2.
• [21]Timmerman HM, Koning CJ, Mulder L, Rombouts FM, Beynen AC: Monostrain, multistrain and multispecies probiotics–A comparison of functionality and efficacy. Int J Food Microbiol 2004, 96:219-233.
• [22]Sanabria ER, Pereira MF, Dolnikoff MS, Andrade IS, Ferreira AT, Cavalheiro EA, Fernandes MJ: Deficit in hippocampal long-term potentiation in monosodium glutamate-treated rats. Brain Res Bull 2002, 59:47-51.
• [23]Bernardis LL, Patterson BD: Correlation between ’Lee index’ and carcass fat content in weanling and adult female rats with hypothalamic lesions. J Endocrinol 1968, 40:527-528.
• [24]Vogeser M, Konig D, Frey I, Predel HG, Parhofer KG, Berg A: Fasting serum insulin and the homeostasis model of insulin resistance (HOMA-IR) in the monitoring of lifestyle interventions in obese persons. Clin Biochem 2007, 40:964-968.
• [25]Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ, Nonalcoholic Steatohepatitis Clinical Research Network: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
• [26]Genoni G, Prodam F, Marolda A, Giglione E, Demarchi I, Bellone S, Bona G: Obesity and infection: two sides of one coin. Eur J Pediatr 2014, 173:25-32.
• [27]McAllister EJ, Dhurandhar NV, Keith SW, Aronne LJ, Barger J, Baskin M, Benca RM, Biggio J, Boggiano MM, Eisenmann JC, Elobeid M, Fontaine KR, Gluckman P, Hanlon EC, Katzmarzyk P, Pietrobelli A, Redden DT, Ruden DM, Wang C, Waterland RA, Wright SM, Allison DB: Ten putative contributors to the obesity epidemic. Crit Rev Food Sci Nutr 2009, 49:868-913.
• [28]Ninomiya K: Natural occurrence. Food Rev Int 1998, 14:177-211.
• [29]Kwok RHM: Chinese-restaurant syndrome. N Engl J Med 1968, 278:796.
• [30]He K, Du S, Xun P, Sharma S, Wang H, Zhai F, Popkin B: Consumption of monosodium glutamate in relation to incidence of overweight in Chinese adults: China Health and Nutrition Survey (CHNS). Am J Clin Nutr 2011, 93:1328-1336.
• [31]He K, Zhao L, Daviglus ML, Dyer AR, Van Horn L, Garside D, Zhu L, Guo D, Wu Y, Zhou B, Stamler J: Association of monosodium glutamate intake with overweight in Chinese adults: the INTERMAP Study. Obesity (Silver Spring) 2008, 16:1875-1880.
• [32]Nagata M, Suzuki W, Iizuka S, Tabuchi M, Maruyama H, Takeda S, Aburada M, Miyamoto K: Type 2 diabetes mellitus in obese mouse model induced by monosodium glutamate. Exp Anim 2006, 55:109-115.
• [33]Beas-Zarate C, Perez-Vega M, Gonzalez-Burgos I: Neonatal exposure to monosodium L-glutamate induces loss of neurons and cytoarchitectural alterations in hippocampal CA1 pyramidal neurons of adult rats. Brain Res 2002, 952:275-281.
• [34]Lorden JF, Caudle A: Behavioral and endocrinological effects of single injections of monosodium glutamate in the mouse. Neurobehav Toxicol Teratol 1986, 8:509-519.
• [35]Oida K, Nakai T, Hayashi T, Miyabo S, Takeda R: Plasma lipoproteins of monosodium glutamate-induced obese rats. Int J Obes 1984, 8:385-391.
• [36]Collison KS, Maqbool Z, Saleh SM, Inglis A, Makhoul NJ, Bakheet R, Al-Johi M, Al-Rabiah R, Zaidi MZ, Al-Mohanna FA: Effect of dietary monosodium glutamate on trans fat-induced nonalcoholic fatty liver disease. J Lipid Res 2009, 50:1521-1537.
• [37]Diniz YS, Faine LA, Galhardi CM, Rodrigues HG, Ebaid GX, Burneiko RC, Cicogna AC, Novelli EL: Monosodium glutamate in standard and high-fiber diets: metabolic syndrome and oxidative stress in rats. Nutrition 2005, 21:749-755.
• [38]Ley RE, Turnbaugh PJ, Klein S, Gordon JI: Microbial ecology: human gut microbes associated with obesity. Nature 2006, 444:1022-1023.
• [39]Zhang H, DiBaise JK, Zuccolo A, Kudrna D, Braidotti M, Yu Y, Parameswaran P, Crowell MD, Wing R, Rittmann BE, Krajmalnik-Brown R: Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci U S A 2009, 106:2365-2370.
• [40]Schwiertz A, Taras D, Schafer K, Beijer S, Bos NA, Donus C, Hardt PD: Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring) 2009, 18:190-195.
• [41]Duncan SH, Lobley GE, Holtrop G, Ince J, Johnstone AM, Louis P, Flint HJ: Human colonic microbiota associated with diet, obesity and weight loss. Int J Obes (Lond) 2008, 32:1720-1724.
• [42]Kalliomaki M, Collado MC, Salminen S, Isolauri E: Early differences in fecal microbiota composition in children may predict overweight. Am J Clin Nutr 2008, 87:534-538.
• [43]Yoon JC, Chickering TW, Rosen ED, Dussault B, Qin Y, Soukas A, Friedman JM, Holmes WE, Spiegelman BM: Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation. Mol Cell Biol 2000, 20:5343-5349.
• [44]Backhed F, Manchester JK, Semenkovich CF, Gordon JI: Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A 2007, 104:979-984.
• [45]Aronsson L, Huang Y, Parini P, Korach-Andre M, Hakansson J, Gustafsson JA, Pettersson S, Arulampalam V, Rafter J: Decreased fat storage by Lactobacillus paracasei is associated with increased levels of angiopoietin-like 4 protein (ANGPTL4). PLoS One 2010, 5(9):e13087.
• [46]Fleissner CK, Huebel N, Abd El-Bary MM, Loh G, Klaus S, Blaut M: Absence of intestinal microbiota does not protect mice from diet-induced obesity. Br J Nutr 2010, 104:919-929.
• [47]Stappenbeck TS, Hooper LV, Gordon JI: Developmental regulation of intestinal angiogenesis by indigenous microbes via Paneth cells. Proc Natl Acad Sci U S A 2002, 99:15451-15455.
• [48]Denechaud PD, Dentin R, Girard J, Postic C: Role of ChREBP in hepatic steatosis and insulin resistance. FEBS Lett 2008, 582:68-73.
• [49]Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, Muir AI, Wigglesworth MJ, Kinghorn I, Fraser NJ, Pike NB, Strum JC, Steplewski KM, Murdock PR, Holder JC, Marshall FH, Szekeres PG, Wilson S, Ignar DM, Foord SM, Wise A, Dowell SJ: The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem 2003, 278:11312-11319.
• [50]Le Poul E, Loison C, Struyf S, Springael JY, Lannoy V, Decobecq ME, Brezillon S, Dupriez V, Vassart G, Van Damme J, Parmentier M, Detheux M: Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem 2003, 278:25481-25489.
• [51]Samuel BS, Shaito A, Motoike T, Rey FE, Backhed F, Manchester JK, Hammer RE, Williams SC, Crowley J, Yanagisawa M, Gordon JI: Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc Natl Acad Sci U S A 2008, 105:16767-16772.
• [52]Bjursell M, Admyre T, Goransson M, Marley AE, Smith DM, Oscarsson J, Bohlooly YM: Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet. Am J Physiol Endocrinol Metab 2010, 300:E211-220.
• [53]Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, Muccioli GG, Delzenne NM: Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009, 58:1091-1103.
• [54]de La Serre CB, Ellis CL, Lee J, Hartman AL, Rutledge JC, Raybould HE: Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am J Physiol Gastrointest Liver Physiol 2010, 299:G440-448.
• [55]Cani PD, Delzenne NM: Gut microflora as a target for energy and metabolic homeostasis. Curr Opin Clin Nutr Metab Care 2007, 10:729-734.
• [56]Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, Waget A, Delmée E, Cousin B, Sulpice T, Chamontin B, Ferrières J, Tanti JF, Gibson GR, Casteilla L, Delzenne NM, Alessi MC, Burcelin R: Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56:1761-1772.
• [57]Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R: Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008, 57:1470-1481.
• [58]Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS: TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006, 116:3015-3025.
• [59]Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, Gibson GR, Delzenne NM: Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007, 50:2374-2383.
• [60]Membrez M, Blancher F, Jaquet M, Bibiloni R, Cani PD, Burcelin RG, Corthesy I, Mace K, Chou CJ: Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB J 2008, 22:2416-2426.
• [61]Tabuchi M, Ozaki M, Tamura A, Yamada N, Ishida T, Hosoda M, Hosono A: Antidiabetic effect of Lactobacillus GG in streptozotocin-induced diabetic rats. Biosci Biotechnol Biochem 2003, 67:1421-1424.
• [62]Yadav H, Jain S, Sinha PR: Effect of Dahi containing Lactococcus lactis on the progression of diabetes induced by a high-fructose diet in rats. Biosci Biotechnol Biochem 2006, 70:1255-1258.
• [63]Yadav H, Jain S, Sinha PR: Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. Nutrition 2007, 23:62-68.
• [64]de Carvalho PP, Vargas AM, da Silva JL, Nunes MT, Machado UF: GLUT4 protein is differently modulated during development of obesity in monosodium glutamate-treated mice. Life Sci 2002, 71:1917-1928.
• [65]de Souza CT, Nunes WM, Gobatto CA, de Mello MA: Insulin secretion in monosodium glutamate (MSG) obese rats submitted to aerobic exercise training. Physiol Chem Phys Med NMR 2003, 35:43-53.
• [66]Combs TP, Pajvani UB, Berg AH, Lin Y, Jelicks LA, Laplante M, Nawrocki AR, Rajala MW, Parlow AF, Cheeseboro L, Ding YY, Russell RG, Lindemann D, Hartley A, Baker GR, Obici S, Deshaies Y, Ludgate M, Rossetti L, Scherer PE: A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 2004, 145:367-383.
• [67]Perello M, Gaillard RC, Chisari A, Spinedi E: Adrenal enucleation in MSG-damaged hyperleptinemic male rats transiently restores adrenal sensitivity to leptin. Neuroendocrinology 2003, 78:176-184.
• [68]Chen W, Wang LL, Liu HY, Long L, Li S: Peroxisome proliferator-activated receptor delta-agonist, GW501516, ameliorates insulin resistance, improves dyslipidaemia in monosodium L-glutamate metabolic syndrome mice. Basic Clin Pharmacol Toxicol 2008, 103:240-246.
• [69]Pallett AL, Morton NM, Cawthorne MA, Emilsson V: Leptin inhibits insulin secretion and reduces insulin mRNA levels in rat isolated pancreatic islets. Biochem Biophys Res Commun 1997, 238:267-270.